Outlook Therapeutics, Inc. (OTLK)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
$0.6450−$0.0108 (−1.65%) on the dayAs of the close; data may be delayed.
OTLK price, last 12 months
Key stats
- Previous close
- $0.6558
- Open
- $0.6600
- Day range
- $0.6360 – $0.6787
- 52-week range
- $0.1611 – $2.54
- Volume
- 2.9M
- Avg volume (20 days)
- 4.4M
- Market cap
- $155.7M
Performance
1W−1.2%
1M+3.5%
3M−62.3%
6M+207.1%
YTD−59.2%
1Y−34.8%
vs S&P 500, 1Y−51.5 pts
Technicals and fundamentals
About Outlook Therapeutics, Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $155.7M